Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Heuser

Showing results (201-210 of 280) with videos related to

Pageof 28
Sort By:
Blood|August 2, 2022
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapyEunice S Wang, Pau Montesinos, Mark D Minden, et al.
Leukemia|April 28, 2025
Prognostic impact of clonal representation of myelodysplasia-related gene mutations in acute myeloid leukemiaRabea Mecklenbrauck, Nora Borchert, Razif Gabdoulline, et al.
Blood|August 29, 2013
Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stromaIsabel Ben-Batalla, Alexander Schultze, Mark Wroblewski, et al.
Cancer Discovery|March 9, 2023
Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/VenetoclaxAlexander Waclawiczek, Aino-Maija Leppä, Simon Renders, et al.
Nature Communications|May 4, 2019
Clonal evolution patterns in acute myeloid leukemia with NPM1 mutationSibylle Cocciardi, Anna Dolnik, Silke Kapp-Schwoerer, et al.
Blood Advances|February 12, 2025
Late-onset telomere biology disorders in adults: clinical insights and treatment outcomes from a retrospective registry cohortMareike Tometten, Fabian Beier, Martin Kirschner, et al.
Blood Advances|December 22, 2020
Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implicationNikolaus Jahn, Tobias Terzer, Eric Sträng, et al.
Blood|August 20, 2013
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AMLAnuhar Chaturvedi, Michelle Maria Araujo Cruz, Nidhi Jyotsana, et al.
Cancer Cell|July 12, 2011
Cell of origin in AML: susceptibility to MN1-induced transformation is regulated by the MEIS1/AbdB-like HOX protein complexMichael Heuser, Haiyang Yun, Tobias Berg, et al.
Blood Advances|April 30, 2021
Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutationsMichael Heuser, Bennet Heida, Konstantin Büttner, et al.
Pageof 28

Showing results (201-210 of 280) with videos related to

Sort By:
Pageof 28
Blood|August 2, 2022
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapyEunice S Wang, Pau Montesinos, Mark D Minden, et al.
Leukemia|April 28, 2025
Prognostic impact of clonal representation of myelodysplasia-related gene mutations in acute myeloid leukemiaRabea Mecklenbrauck, Nora Borchert, Razif Gabdoulline, et al.
Blood|August 29, 2013
Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stromaIsabel Ben-Batalla, Alexander Schultze, Mark Wroblewski, et al.
Cancer Discovery|March 9, 2023
Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/VenetoclaxAlexander Waclawiczek, Aino-Maija Leppä, Simon Renders, et al.
Nature Communications|May 4, 2019
Clonal evolution patterns in acute myeloid leukemia with NPM1 mutationSibylle Cocciardi, Anna Dolnik, Silke Kapp-Schwoerer, et al.
Blood Advances|February 12, 2025
Late-onset telomere biology disorders in adults: clinical insights and treatment outcomes from a retrospective registry cohortMareike Tometten, Fabian Beier, Martin Kirschner, et al.
Blood Advances|December 22, 2020
Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implicationNikolaus Jahn, Tobias Terzer, Eric Sträng, et al.
Blood|August 20, 2013
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AMLAnuhar Chaturvedi, Michelle Maria Araujo Cruz, Nidhi Jyotsana, et al.
Cancer Cell|July 12, 2011
Cell of origin in AML: susceptibility to MN1-induced transformation is regulated by the MEIS1/AbdB-like HOX protein complexMichael Heuser, Haiyang Yun, Tobias Berg, et al.
Blood Advances|April 30, 2021
Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutationsMichael Heuser, Bennet Heida, Konstantin Büttner, et al.
Pageof 28